Leishmania model for microbial virulence: The relevance of parasite multiplication and pathoantigenicity

Acta Tropica

Volumn 85, Issue 3, 2003, Pages 375-390

  Chang, Kwang Poo ^a   Reed, Steven G ^b   McGwire, Bradford S ^c,d   Soong, Lynn ^e  

^a Department of Psychology Univ Hlth Sci The Chicago Med S   (United States)

^b Infect Disease Research Institute   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Infection; Leishmania; Leishmaniasis; Live vaccine; Macrophage; Microbial virulence; Pathoantigenicity

Indexed keywords

CYTOPLASM PROTEIN; EPITOPE; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

LEISHMANIASIS;

AMASTIGOTE; ANTIGENICITY; CELL VACUOLE; CYTOLYSIS; IMMUNOPATHOLOGY; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MICROBIAL GROWTH; NONHUMAN; PARASITE VIRULENCE; PHENOTYPE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ANIMAL; BLOOD; HOST PARASITE INTERACTION; HUMAN; IMMUNOLOGY; MOUSE; PARASITOLOGY; PATHOGENICITY; ULTRASTRUCTURE; VIRULENCE;

LEISHMANIA AMAZONENSIS; NASO HEXACANTHUS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; HOST-PARASITE RELATIONS; HUMANS; LEISHMANIA; LEISHMANIASIS; MACROPHAGES; MICE; VIRULENCE;

EID: 0037347019     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(02)00238-3     Document Type: Review

References (87)

1. Aebischer T., Wolfram M., Patzer S.I., Ilg T., Wiese M., Overath P. Subunit vaccination of mice against New World cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 68:(3):2000;1328-1336.
2. Aga E., Katschinski D.M., Van Zandbergen G., Laufs H., Hansen B., Muller K., Solbach W., Laskay T. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J. Immunol. 169:(2):2002;898-905.
3. Alexander J., Russell D.G. The interaction of Leishmania species with macrophages. Adv. Parasitol. 31:1992;175-254.
4. Alexander J., Coombs G.H., Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:1998;6794-6801.
5. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:(2):1997;298-319.
6. Antoine J.C., Prina E., Lang T., Courret N. The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends Microbiol. 6:(10):1998;392-401.
7. Antoine J.C., Lang T., Prina E., Courret N., Hellio R. H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. J. Cell Sci. 112 (Pt 15):1999;2559-2570.
8. Arbuthnott J.P. Role of exotoxins in bacterial pathogenicity. J. Appl. Bacteriol. 44:(3):1978;329-345.
9. Arnoult D., Akarid K., Grodet A., Petit P.X., Estaquier J., Ameisen J.C. On the evolution of programmed cell death: apoptosis of the unicellular eukaryote Leishmania major involves cysteine proteinase activation and mitochondrion permeabilization. Cell Death Differ. 9:(1):2002;65-81.
10. Barry J.D., McCulloch R. Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Adv. Parasitol. 49:2001;1-70.
11. Bates P.A. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology. 108 (Pt 1):1994;1-9.
12. Belkaid Y., Kamhawi S., Modi G., Valenzuela J., Noben-Trauth N., Rowton E., Ribeiro J., Sacks D.L. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188:(10):1998;1941-1953.
13. Beverley S.M., Turco S.J. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania. Trends Microbiol. 6:(1):1998;35-40.
14. Bhakdi S. Microbial toxins. Wien Klin. Wochenschr. 110:(19):1998;660-668.
15. Bogdan C., Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int. J. Parasitol. 28:(1):1998;121-134.
16. Bogdan C., Rollinghoff M. How do protozoan parasites survive inside macrophages? Parasitol. Today. 15:(1):1999;22-28.
17. Bryceson A.D.M. Leishmaniasis. Cokk G.C. Manson's Tropical Diseases. Twentieth ed :1996;1213-1246 Saunders, London.
18. Buates S., Matlashewski G. General suppression of macrophage gene expression during Leishmania donovani infection. J. Immunol. 166:(5):2001;3416-3422.
19. Burns J.M. Jr, Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., Reed S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA. 90:1993;775-779.
20. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Skeiky Y.A., Reed S.G., Grimaldi G. Jr. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:(6):2001;4103-4108.
21. Chang K.-P. Human cutaneous Leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science. 209:(4462):1980;1240-1242.
22. Chang K.-P. Evolution and regulation of Leishmania virulence. Current Trends in Leishmania Research. 1993;15-28 CSIR Symposium, CSIR Press, New Dehli.
23. Chang K.-P., Fong D. Cellular and molecular mechanisms of intracellular symbiosis in leishmaniasis. Int. Rev. Cytol. Suppl. 14:1983;267-305.
24. Chang K.-P., Hendricks D.L. Laboratory maintenance of leishmaniae. Chang K.-P., Bray R.S. Human Parasitic Diseases - Leishmaniasis. 1:1985;213-246 Elsevier Biomedical Press, Amsterdam.
25. Chang K.-P., McGwire B.S. Leishmania virulence and regulation. Kinetoplastid. Biol. Dis. 1:2002;1-7.
26. Chang K.-P., Nacy C.A., Pearson R.D. Intracellular parasitism of macrophages in leishmaniasis: in vitro systems and their applications. Methods Enzymol. 132:1986;603-626.
27. Chang K.-P., Chaudhuri G., Fong D. Molecular determinants of Leishmania virulence. Annu. Rev. Microbiol. 44:1990;499-529.
28. Chang K.-P., Akman L., Nielsen J.S. Leishmania virulence and genetic heterogeneity. Clin. Dermatol. 17:(3):1999;269-273.
29. Cheever A.W., Hoffmann K.F., Wynn T.A. Immunopathology of Schistosomiasis mansoni in mice and men. Immunol. Today. 21:(9):2000;465-466.
30. Chen D.Q., Kolli B.K., Yadava N., Lu H.G., Gilman-Sachs A., Peterson D.A., Chang K.-P. Episomal expression of specific sense and antisense mRNAs in Leishmania amazonensis: modulation of gp63 level in promastigotes and their infection of macrophages in vitro. Infect. Immun. 68:(1):2000;80-86.
31. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., Modabber F., Campos-Neto A., Reed S.G. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:(8):2002;4215-4225.
32. Colmenares M., Kar S., Goldsmith-Pestana K., McMahon-Pratt D. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans. R. Soc. Trop. Med. Hyg. 96 Suppl 1:2002;S3-7.
33. Courret N., Frehel C., Gouhier N., Pouchelet M., Prina E., Roux P., Antoine J.C. Biogenesis of Leishmania-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. J. Cell Sci. 115:(Pt 11):2002;2303-2316.
34. Delgado O., Feliciangeli M.D., Coraspe V., Silva S., Perez A., Arias J. Value of a dipstick based on recombinant rK39 antigen for differential diagnosis of American visceral leishmaniasis from other sympatic endemic diseases in Venezuela. Parasite. 8:(4):2001;355-357.
35. Doyle P.S., Engel J.C., Pimenta P.F., da Silva P.P., Dwyer D.M. Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees. Exp. Parasitol. 73:(3):1991;326-334.
36. Finlay B.B., Falkow S. Common themes in microbial pathogenicity revisited. Microbiol. Mol. Biol. Rev. 61:(2):1997;136-169.
37. Fong D., Chang K.-P. Tubulin biosynthesis in the developmental cycle of a parasitic protozoan, Leishmania mexicana: changes during differentiation of motile and nonmotile stages. Proc. Natl. Acad. Sci. USA. 78:(12):1981;7624-7628.
38. Gomes N.A., Gattass C.R., Barreto-De-Souza V., Wilson M.E., DosReis G.A. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kala-azar. J. Immunol. 164:(4):2000;2001-2008.
39. Ghosh A., Zhang W.W., Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine. 20:(1-2):2001;59-66.
40. Haberer J.E., Da-Cruz A.M., Soong L., Oliveira-Neto M.P., Rivas L., McMahon-Pratt D., Coutinho S.G. Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infect. Immun. 66:(7):1998;3100-3105.
41. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:(2):2001;229-234.
42. Henriques C., de Souza W. Redistribution of plasma-membrane surface molecules during formation of the Leishmania amazonensis-containing parasitophorous vacuole. Parasitol. Res. 86:(3):2000;215-225.
43. Kane M.M., Mosser D.M. Leishmania parasites and their ploys to disrupt macrophage activation. Curr. Opin. Hematol. 7:(1):2000;26-31.
44. Kar S., Soong L., Colmenares M., Goldsmith-Pestana K., McMahon-Pratt D. The immunologically protective P-4 antigen of Leishmania amastigotes. A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. J. Biol. Chem. 275:(48):2000;37789-37797.
45. + T cells. J. Immunol. 159:(4):1997;1828-1834.
46. Kumar R., Pai K., Pathak K., Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 8:(6):2001;1220-1224.
47. Lee N., Bertholet S., Debrabant A., Muller J., Duncan R., Nakhasi H.L. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ. 9:(1):2002;53-64.
48. Locksley R.M., Pingel S., Lacy D., Wakil A.E., Bix M., Fowell D.J. Susceptibility to infectious diseases: Leishmania as a paradigm. J. Infect. Dis. 179:(Suppl. 2):1999;S305-308.
49. Lubran M.M. Bacterial toxins. Ann. Clin. Lab. Sci. 18:(1):1988;58-71.
50. McGwire B., Chang K.-P. Genetic rescue of surface metalloproteinase (gp63)-deficiency in Leishmania amazonensis variants increases their infection of macrophages at the early phase. Mol. Biochem. Parasitol. 66:(2):1994;345-347.
51. McGwire B.S., O'Connell W.A., Chang K.-P., Engman D.M. Extracellular release of the glycosylphosphatidylinositol (GPI)-linked Leishmania surface metalloprotease, gp63, is independent of GPI phospholipolysis: implications for parasite virulence. J. Biol. Chem. 277:(11):2002;8802-8809.
52. Mensa-Wilmot K., Garg N., McGwire B.S., Lu H.G., Zhong L., Armah D.A., LeBowitz J.H., Chang K.-P. Roles of free GPIs in amastigotes of Leishmania. Mol. Biochem. Parasitol. 99:(1):1999;103-116.
53. Middlebrook J.L., Dorland R.B. Bacterial toxins: cellular mechanisms of action. Microbiol. Rev. 48:(3):1984;199-221.
54. Moll H., Berberich C. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis. Immunobiology. 204:(5):2001;659-666.
55. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science. 268:(5210):1995;563-566.
56. Moore K.J., Matlashewski G. Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J. Immunol. 152:(6):1994;2930-2937.
57. Moreira M.E., Del Portillo H.A., Milder R.V., Balanco J.M., Barcinski M.A. Heat shock induction of apoptosis in promastigotes of the unicellular organism Leishmania (Leishmania) amazonensis. J. Cell Physiol. 167:(2):1996;305-313.
58. Olsnes S., Kozlov J.V., van Deurs B., Sandvig K. Bacterial protein toxins acting on intracellular targets. Semin. Cell Biol. 2:(1):1991;7-14.
59. Ozensoy S., Ozbel Y., Turgay N., Alkan M.Z., Gul K., Gilman-Sachs A., Chang K.-P., Reed S.G., Ozcel M.A. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. Am. J. Trop. Med. Hyg. 59:(3):1998;363-369.
60. Pan A.A., Duboise S.M., Eperon S., Rivas L., Hodgkinson V., Traub-Cseko Y., McMahon-Pratt D. Developmental life cycle of Leishmania - cultivation and characterization of cultured extracellular amastigotes. J. Eukaryot. Microbiol. 40:(2):1993;213-223.
61. Papadopoulou B., Roy G., Breton M., Kundig C., Dumas C., Fillion I., Singh A.K., Olivier M., Ouellette M. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70:(1):2002;62-68.
62. Pearson R.D., Steigbigel R.T. Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes. J. Immunol. 127:(4):1981;1438-1443.
63. Piedrafita D., Xu D., Hunter D., Harrison R.A., Liew F.Y. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J. Immunol. 163:(3):1999;1467-1472.
64. Probst P., Stromberg E., Ghalib H.W., Mozel M., Badaro R., Reed S.G., Webb J.R. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J. Immunol. 166:(1):2001;498-505.
65. Qi H., Popov V., Soong L. Leishmania amazonensis-dendritic cell interactions in vitro and the priming of parasite-specific CD4(+) T cells in vivo. J. Immunol. 167:(8):2001;4534-4542.
66. Qu J.Q., Zhong L., Masoom-Yasinzai M., Abdur-Rab M., Aksu H.S., Reed S.G., Chang K.-P., Gilman-Sachs A. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans. R. Soc. Trop. Med. Hyg. 88:(5):1994;543-545.
67. Ramazeilles C., Juliano L., Chagas J.R., Rabinovitch M. The anti-leishmanial activity of dipeptide esters on Leishmania amazonensis amastigotes. Parasitology. 100:(Pt 2):1990;201-207.
68. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. J. Exp. Med. 194:(3):2001;F7-F9.
69. Reed S.G., Scott P. T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5:(4):1993;524-531.
70. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:1995;151-177.
71. Requena J.M., Alonso C., Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol. Today. 16:(6):2000;246-250.
72. Rittig M.G., Bogdan C. Leishmania-host-cell interaction: complexities and alternative views. Parasitol. Today. 16:(7):2000;292-297.
73. 2+-ATPase gene lmaa1 enhances virulence. Cell Microbiol. 4:(2):2002;117-126.
74. Saar Y., Ransford A., Waldman E., Mazareb S., Amin-Spector S., Plumblee J., Turco S.J., Zilberstein D. Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol. Biochem. Parasitol. 95:(1):1998;9-20.
75. Sah J.F., Ito H., Kolli B.K., Peterson D.A., Sassa S., Chang K.-P. Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J. Biol. Chem. 277:(17):2002;14902-14909.
76. Schaible U.E., Schlesinger P.H., Steinberg T.H., Mangel W.F., Kobayashi T., Russell D.G. Parasitophorous vacuoles of Leishmania mexicana acquire macromolecules from the host cell cytosol via two independent routes. J. Cell Sci. 112 (Pt 5):1999;681-693.
77. Singh S., Gilman-Sachs A., Chang K.-P., Reed S.G. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J. Parasitol. 81:1995;1000-1003.
78. Singh S., Kumari V., Singh N. Predicting Kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant k39 antigen. Clin. Diagn. Lab. Immunol. 9:(3):2002;568-572.
79. Solbach W., Laskay T. The host response to Leishmania infection. Adv. Immunol. 74:2000;275-317.
80. Soong L., Chang C.H., Sun J., Longley B.J., Ruddle N.H. Jr, Flavell R.A., McMahon-Pratt D. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 158:(11):1997;5374-5383.
81. Soto M., Requena J.M., Quijada L., Garcia M., Guzman F., Patarroyo M.E. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol. Lett. 48:(3):1995;209-214.
82. Soto M., Requena J.M., Quijada L., Guzman F., Patarroyo M.E., Alonso C. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol. Lett. 48:(1):1995;23-28.
83. Stetson D., Mohrs M., Mallet-Designe V., Teyton L., Locksley R. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity. 17:(2):2002;191.
84. Sundar S., Reed S.G., Singh V.P., Kumar P.C., Murray H.W. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet. 351:(9102):1998;563-565.
85. Terabe M., Kuramochi T., Ito M., Hatabu T., Sanjoba C., Chang K.-P., Onodera T., Matsumoto Y. CD4(+) cells are indispensable for ulcer development in murine cutaneous leishmaniasis. Infect. Immun. 68:(8):2000;4574-4577.
86. Titus R.G., Gueiros-Filho F.J., de Freitas L.A., Beverley S.M. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA. 92:(22):1995;10267-10271.
87. Tsikaris V., Sakarellos C., Sakarellos-Daitsiotis M., Cung M.T., Marraud M., Konidou G., Tzinia A., Soteriadou K.P. Use of sequential oligopeptide carriers (SOCn) in the design of potent Leishmania gp63 immunogenic peptides. Pept. Res. 9:(5):1996;240-247.